从资金流向上来看，当日医疗器械板块主力资金净流出6.21亿元，游资资金净流入1.32亿元，散户资金净 流入4.89亿元。医疗器械板块个股资金流向见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688358 | 祥生医疗 | 32.90 | 9.30% | 5.50万 | | 1.77亿 | | 300326 | ST凯利 | 5.88 | 3.70% | 18.20万 | | 1.06亿 | | 688289 | 圣湘生物 | 20.50 | 3.07% | 11.12万 | | 2.27亿 | | 300677 | 英科医疗 | 37.76 | 2.61% | 21.41万 | | 8.11亿 | | 300358 | 楚天科技 | 9.11 | 2.59% | 41.69万 | | 3.76亿 | | 688212 | 澳华内镜 | 49.14 | 2.55% | 1.92万 | | 9322.40万 | | 688026 | 洁特生物 | 18.29 | 1.72 ...

Core Viewpoint - The article discusses the performance of the Science and Technology Innovation Enhanced ETF (588520), highlighting its recent market activity and key holdings [1]. Group 1: ETF Performance - The Science and Technology Innovation Enhanced ETF (588520) opened with a gain of 0.31%, priced at 1.310 yuan [1]. - Since its inception on June 27, 2025, the fund has achieved a return of 30.89%, with a one-month return of 6.09% [1]. Group 2: Key Holdings - Major holdings in the ETF include: - Semiconductor Manufacturing International Corporation (down 0.99%) - Cambricon Technologies (up 0.14%) - Jianyuan Technology (up 6.32%) - Transsion Holdings (up 2.38%) - Zhuhai CosMX Battery Co., Ltd. (up 1.21%) - Western Superconducting Technologies (up 0.17%) - Xiangsheng Medical (up 0.81%) - Trina Solar (down 0.31%) - China Railway Signal & Communication Corp (unchanged) - Saintshine Medical (up 0.70%) [1].

圣湘生物科技股份有限公司 关于自愿披露相关产品取得医疗器械注册证 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 圣湘生物科技股份有限公司（以下简称"公司"或"圣湘生物"）的产品金黄色葡萄 球菌及耐甲氧西林金黄色葡萄球菌核酸检测试剂盒（荧光 PCR 法）于近日收到由国 家药品监督管理局颁发的《医疗器械注册证》，现将相关情况公告如下： 证券代码：688289 证券简称：圣湘生物 公告编号：2025-063 一、产品注册相关情况 二、对公司的影响 抗生素耐药性（AMR）是 21 世纪全球公共卫生面临的重大挑战，据相关数据显 示，每年与耐药相关的死亡病例接近 500 万例，其中，耐甲氧西林金黄色葡萄球菌 （MRSA）作为最具威胁性的耐药病原之一，仅 2019 年就造成全球超过 10 万例死亡。 MRSA 对甲氧西林和所有β-内酰胺类抗生素（如青霉素、头孢菌素等）耐药，具备高 发病率、高死亡率及强传播性，已被世界卫生组织（WHO）列入《2024 年细菌类重 点病原体目录》，以提示全球对其耐药性挑战的高度关注。 与甲氧西林敏 ...

Core Viewpoint - Shengxiang Bio (688289.SH) has received a medical device registration certificate from the National Medical Products Administration for its Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus nucleic acid detection kit, indicating a significant regulatory approval for its product line [1] Company Summary - The product is a nucleic acid detection kit using fluorescent PCR method, designed for the qualitative detection of Staphylococcus aureus species-specific fragments and the mecA gene of Methicillin-resistant Staphylococcus aureus in human sputum samples [1]

智通财经APP讯，圣湘生物(688289.SH)发布公告，公司产品金黄色葡萄球菌及耐甲氧西林金黄色葡萄 球菌核酸检测试剂盒(荧光PCR法)于近日收到由国家药品监督管理局颁发的《医疗器械注册证》。本试 剂盒用于体外定性检测人痰液样本中金黄色葡萄球菌种属特异性片段及耐甲氧西林金黄色葡萄球菌 mecA基因的核酸。 ...

圣湘生物公告，公司产品金黄色葡萄球菌及耐甲氧西林金黄色葡萄球菌核酸检测试剂盒（荧光PCR 法）于近日收到由国家药品监督管理局颁发的《医疗器械注册证》。该试剂盒用于体外定性检测人痰液 样本中金黄色葡萄球菌种属特异性片段及耐甲氧西林金黄色葡萄球菌 mecA 基因的核酸。 ...

Group 1 - The core point of the article highlights the performance of the Kexin Enhanced ETF (588520), which opened down 0.70% at 1.285 yuan on September 18 [1] - The major holdings of the Kexin Enhanced ETF include companies like SMIC, which rose by 2.21%, and Cambrian, which increased by 4.58%, while other stocks like Jianyuan Technology and Zhuhai Guanyu experienced slight declines [1] - The Kexin Enhanced ETF's performance benchmark is the Shanghai Stock Exchange Science and Technology Innovation Board Composite Price Index, managed by Yongying Fund Management Co., Ltd. Since its establishment on June 27, 2025, it has returned 29.54%, with a monthly return of 12.36% [1]

Core Viewpoint - The company, Shengxiang Biotechnology Co., Ltd., has announced a cash dividend of 0.262 yuan per share for the first half of 2025, following the approval of its profit distribution plan by the board of directors [1][3][10]. Summary by Relevant Sections Dividend Distribution Plan - The annual dividend for the first half of 2025 is set at 0.262 yuan per share [1][7]. - The total number of shares eligible for the dividend distribution is 574,178,605 shares after excluding 5,209,401 shares held in the company's repurchase account [3][7]. - The total cash dividend to be distributed amounts to approximately 150.43 million yuan (including tax) [3][7]. Shareholder Eligibility - The dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the day before the equity registration date [1][3]. Taxation Details - For individual shareholders holding shares for over one year, the dividend income is exempt from personal income tax, resulting in a net cash dividend of 0.262 yuan per share [10][11]. - For shares held for less than one year, the company will not withhold personal income tax at the time of distribution, but tax will be calculated upon the transfer of shares [10][11]. - Qualified Foreign Institutional Investors (QFII) will have a 10% corporate income tax withheld, resulting in a net cash dividend of 0.2358 yuan per share [12]. Implementation Method - Shares held in the company's repurchase account will not participate in the profit distribution [8]. - Shareholders who have completed designated transactions can receive their cash dividends on the distribution date through their designated securities firms [8][9].

证券日报网讯 9月16日晚间，圣湘生物发布2025年半年度权益分派实施公告称，公司2025年半年度权益 分派方案为每股现金红利0.262元（含税），股权登记日为2025年9月22日，除权（息）日及现金红利发 放日均为2025年9月23日。 （文章来源：证券日报） ...

湖南启元律师事务所 关于圣湘生物科技股份有限公司 差异化权益分派事项之 法律意见书 2025 年 09 月 1 致：圣湘生物科技股份有限公司 湖南启元律师事务所（以下简称"本所"）接受圣湘生物科技股份有限公司 （以下简称"公司""圣湘生物"）的委托，就公司2025年半年度利润分配所涉 及的差异化权益分派（以下简称"本次差异化权益分派"）相关事项出具本法律 意见。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上海证券交易所上市公 司自律监管指引第7号——回购股份》（以下简称"《回购指引》"）等现行法 律、法规和规范性文件以及《圣湘生物科技股份有限公司公司章程》（以下简称 "《公司章程》"）的有关规定，按照律师行业公认的业务标准、道德规范和勤 勉尽责精神，就公司本次差异化权益分派相关事项出具本法律意见书。 本所（含经办律师）声明如下： （一）本所依据我国法律、法规、地方政府及部门规章、规范性文件及中国 证监会、证券交易所的有关规定以及本法律意见书出具日以前已经发生或者存在 的事实发表法律意见。 （二）本所已严格履行了法定职责，遵循了勤勉尽 ...